

The Institute of Human Virology, Nigeria (IHVN) is a non-governmental organization established in 2004 to address the HIV/AIDS crisis in Nigeria through developing infrastructure for treatment, care, prevention, and support for people living with and those affected with HIV/AIDS. IHVN has now expanded its services to other infectious diseases like tuberculosis and malaria and non-infectious diseases, including cancers.

As a local organization, the Institute is structured to develop and maintain linkages within and outside the country in collaborative ways that support the Government of Nigeria's health sector strategic plans. IHVN key technical and funding partners include the Centers for Disease Control and Prevention (CDC), the Global Fund to Fight AIDS, Tuberculosis and Malaria and the United States Agency for International Development (USAID).



Community Health Worker counseling a client about prevention of mother to child transmission of HIV

Projects:

ACHIEVE: Action to Control HIV Epidemic through Evidence (ACHIEVE) project is an IHVN project funded by the US Government's PEPFAR (US President's Emergency Plan for AIDS Relief) through Centers for Disease Control and Prevention (CDC). ACHIEVE focuses on Anti-retroviral treatment for adult and children (including pregnant women), Prevention of Mother-to-Child Transmission, HIV Testing Services, support to Orphans and Vulnerable Children, Gender-Based Violence support services & training in all the above areas. As of **September 2022**, **679,856** patients received care and support for HIV/AIDS, and **567,150** received ARV drugs and treatment under this project.











Global Fund IHVN is a Principal Recipient for the TB Public Private Mix Scale-up in Nigeria. The grant aims at reducing the TB burden by scaling up TB prevention, diagnostic and treatment services through private sector engagement. **As at September 2022, 143,406 TB cases have been notified by non-national TB program providers** (in private and non-governmental facilities). Through the drug-resistant tuberculosis program that IHVN implemented from June 2011 to December 2018, **9,036** bacteriologically confirmed drug-resistant tuberculosis cases were identified, and **6,515** drug-resistant tuberculosis patients enrolled for treatment. IHVN was also a sub-recipient to FHI 360 providing services in the areas of HTS, PMTCT, ART and TB/HIV services in ten states.

The USAID/Nigeria Tuberculosis Local Organization Network (TB-LON) project is a five-year project to scale up tuberculosis services and find missing TB cases. It started in April 2020 and is engaging stakeholders in strengthening a resilient system for sustainable TB control in Lagos, Ogun, Oyo and Osun states. **As of August 2022, 45,679** tuberculosis cases were identified and notified.





The Accelerating Nutrition Results in Nigeria (ANRiN) project aims at increasing the utilization of quality cost-effective nutrition services for pregnant and lactating women, adolescent girls and children under five years of age. ANRiN, which is supported by the World Bank (International Development Association and Global Financing Facility). IHVN is implementing the ANRiN project in nine Local Government Areas (LGAs) in Kano state. These are, Nasarawa, Kano Municipal, Fagge, Gwale, Tarauni, Kumbostso, DALA, Bunkure and Wudil.

RESEARCH and TRAINING: IHVN has established a center, the International Research Center of Excellence (IRCE) to promote public/private partnership for quality health services, capacity building and research in West Africa. IHVN also conducts biomedical research focusing on HIV/AIDS, malaria, tuberculosis and non-communicable diseases, e.g. cancer and diabetes. Funding institutions for these research projects include, US National Institutes of Health (NIH) and Wellcome Trust. IHVN builds the capacity of health care providers and ancillary workers across all implementation and research activities. As of **September 2022**, **** healthcare professionals have been trained in HIV, TB, and other several areas.

CUMMULATIVE ACHIEVEMENTS IN HIV/AIDS FROM 2004 TO SEPTEMBER 2022

	PEPFAR Funded (ACTION, ACTIONPlus, ACTION PlusUp, ACHIEVE Projects)	Global Fund HIV (project concluded in June 2019)	Total
 Individuals counseled, tested and received results	15,129,461	2,508,810	17,638,271
 Pregnant women counseled, tested and received results	3,696,201	1,550,279	5,246,408
 Pregnant women confirmed positive	112,705	21,679	134,384
 Pregnant women provided anti-retroviral prophylaxis	103,314	18,152	121,466
 Clients cumulatively enrolled in the HIV care program	679,856	104,837	784,693
 Clients cumulatively initiated on ART	567,150	99,262	666,412
 Pediatric clients cumulatively initiated (subset of ART above)	22,414	39,849	62,263
 Clients provided TB treatment	49,423	2,851	52,274
 Number of Orphans and Vulnerable children (OVC) cared for	185,681	N/A	185,681
 Number of Service Delivery Points	ART:360	ART:69	429
	PMTCT:345	PMTCT:347	692
	TB:185	DR-TB:28	213
	HTS:360	HTS:416	776
	OVC:35		35
Number of People Trained	48,864		

KEY Global Fund TB PPM Achievements (from January 2019 to September 2022)

	Target	Achievement	%
Number of notified TB cases (all forms) contributed by non-national TB program providers – private/ non-governmental facilities 	266,534	143,406	54
Treatment success rate: All forms 	90%	94%	103
Number of TB cases with Rifampicin Resistant TB and/or MDR-TB notified 	8,843	1,221	14
Number of MDR-TB patients enrolled for treatment 	8,581	1,182	14
Percentage of TB patients with Drug Susceptible Tuberculosis result (for at least Rifampicin) among the total number of notified (new and retreatment) cases in the same year	75%	75%	100